Clinical trial / 2018
Vitamin D supplementation did not improve overall survival in NSCLC patients, but improved 5-year survival in early-stage adenocarcinoma with low vitamin D.
A randomized, double-blind trial evaluated vitamin D supplements (1,200 IU/day) versus placebo for 1 year in 155 postoperative NSCLC patients followed for a median of 3.3 years. In the total population, no significant difference was observed for RFS or OS between groups. However, among patients with early-stage adenocarcinoma and low 25(OH)D (<20 ng/mL), vitamin D supplementation led to significantly higher 5-year RFS (86% vs. 50%, P = 0.04) and OS (91% vs. 48%, P = 0.02). DBP1 TT and CDX2 AA/AG genotypes were also markers of better prognosis.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 155 patients with non-small cell lung cancer (NSCLC) after operation
- What was measured
- Relapse-free survival (RFS) and overall survival (OS)
THE PAPER
Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.
Akiba T, Morikawa T, Odaka M, Nakada T, Kamiya N, Yamashita M, Yabe M, Inagaki T, Asano H, Mori S, Tsukamoto Y, Urashima M. Clin Cancer Res, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.